India pharma market grows 13% in August as GLP-1 therapies accelerate
India’s pharmaceutical market reached ₹24,800 crore in August, up 13% year-on-year, led by pricing and new launches while volumes rose just 0.6%. Chronic therapies outpaced acute categories, and generic semaglutide launches are rapidly expanding the GLP-1 opportunity despite pressure on sector margins.
What happened
Indian Pharma Market (IPM) · India’s pharma market grew 13% in August, driven by pricing and new launches rather than volumes. GLP-1 therapies are accelerating
Key facts
- IPM revenue grew 13% year-on-year to ₹24,800 crore in August
- Moving annual turnover rose 12.3% year-on-year to ₹2.7 trillion
- Volumes increased 0.6%
- Chronic therapies grew 16%; acute therapies grew 11%
- Respiratory and anti-infectives grew 3%
What changed
India’s pharma market grew 13% in August, driven by pricing and new launches rather than volumes. GLP-1 therapies are accelerating sharply after generic semaglutide launches, while domestic demand offers support amid US tariff and export-market uncertainty.
Why this matters
Prioritize chronic-care and GLP-1 assortment readiness as growth is being driven by new launches and pricing rather than broad-based volume expansion.
What to watch
- Monthly Indian Pharma Market volume growth versus pricing-led revenue growth.
- Number, pricing, and supply availability of generic semaglutide launches.
- GLP-1 prescription growth, refill persistence, and patient discontinuation rates.
- NPPA or other regulatory actions affecting GLP-1 pricing, promotion, or dispensing.
- Pharmacy-chain same-store sales, chronic-versus-acute mix, and gross-margin trends.